3-10142085-A-G

Variant names:

• chr3-10142085-A-G
• rs786202787
• NM_000551.4:c.238A>G

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1 PM2 PM5 PP3_Strong PP5_Very_Strong

The NM_000551.4(VHL):​c.238A>G​(p.Ser80Gly) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S80N) has been classified as Likely pathogenic.

• Frequency: Genomes: not found (cov: 33)
• Consequence: VHL NM_000551.4 missense
• Clinical Significance: Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:3
• Conservation: PhyloP100: 5.72

Genes affected

VHL (HGNC:12687): (von Hippel-Lindau tumor suppressor) This gene encodes a component of a ubiquitination complex. The encoded protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. In addition to oxygen-related gene expression, this protein plays a role in many other cellular processes including cilia formation, cytokine signaling, regulation of senescence, and formation of the extracellular matrix. Variants of this gene are associated with von Hippel-Lindau syndrome, pheochromocytoma, erythrocytosis, renal cell carcinoma, and cerebellar hemangioblastoma. [provided by RefSeq, Jun 2022]

ACMG classification

Verdict is Pathogenic. Variant got 18 ACMG points.

• PM1: In a chain von Hippel-Lindau disease tumor suppressor (size 212) in uniprot entity VHL_HUMAN there are 96 pathogenic changes around while only 8 benign (92%) in NM_000551.4
• PM2: Very rare variant in population databases, with high coverage
• PM5: Other missense variant is known to change same aminoacid residue: Variant chrnull-null-null-null is described in UniProt as null.
• PP3: MetaRNN computational evidence supports a deleterious effect, 0.949
• PP5: Variant 3-10142085-A-G is Pathogenic according to our data. Variant chr3-10142085-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 186220.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
VHL	NM_000551.4	c.238A>G	p.Ser80Gly	missense_variant	Exon 1 of 3	ENST00000256474.3	NP_000542.1
VHL	NM_001354723.2	c.238A>G	p.Ser80Gly	missense_variant	Exon 1 of 3		NP_001341652.1
VHL	NM_198156.3	c.238A>G	p.Ser80Gly	missense_variant	Exon 1 of 2		NP_937799.1
VHL	NR_176335.1	n.308A>G		non_coding_transcript_exon_variant	Exon 1 of 4

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
VHL	ENST00000256474.3	c.238A>G	p.Ser80Gly	missense_variant	Exon 1 of 3	1	NM_000551.4	ENSP00000256474.3

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD4 exome Cov.: 32

GnomAD4 genome Cov.: 33

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:3

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Von Hippel-Lindau syndrome Pathogenic:1

Aug 04, 2021

Clinical Genomics Labs, University Health Network

Significance: Likely pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1

Apr 08, 2022

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

For these reasons, this variant has been classified as Pathogenic. This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 80 of the VHL protein (p.Ser80Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with pheochromocytomas (PMID: 9215674, 12500216; Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 186220). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. This variant disrupts the p.Ser80 amino acid residue in VHL. Other variant(s) that disrupt this residue have been observed in individuals with VHL-related conditions (PMID: 8707293, 27527340), which suggests that this may be a clinically significant amino acid residue. -

Hereditary cancer-predisposing syndrome Pathogenic:1

Mar 25, 2020

Ambry Genetics

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The p.S80G variant (also known as c.238A>G), located in coding exon 1 of the VHL gene, results from an A to G substitution at nucleotide position 238. The serine at codon 80 is replaced by glycine, an amino acid with similar properties. This mutation was detected in a polish individual with bilateral pheochromocytoma (PCC) and absence of any other VHL clinical features. The patient's mother was also reported to have bilateral PCC (Woodward ER et al. Hum Mol Genet. 1997 Jul;6(7):1051-6). This alteration was also detected as a de novo mutation in a 12 year old male diagnosed with bilateral PCC and multiple congenital anomalies including microcephaly, severe hearing loss, and cryptorchidism, and developmental delay (Assadi F & Brackbill EL. Am J Kidney Dis. 2003 Jan;41(1):E3). This alteration was also observed as a somatic mutation in a PCC diagnosed in a 25 year old female (Crona J et al. PLoS One. 2014 Jan 22;9(1):e86756). Multiple other mutations at the same codon have been observed in individuals with Type 2 VHL (Ding X et al. J Neurosurg. 2014 Aug;121(2):384-6; Zhang J et al. J Cancer Res Clin Oncol. 2008 Nov;134(11):1211-8). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Pathogenic	0.84
BayesDel_addAF	Pathogenic	0.38	D
BayesDel_noAF	Pathogenic	0.31
CADD	Uncertain	24
DANN	Uncertain	1.0
DEOGEN2	Pathogenic	0.98	D;.
Eigen	Uncertain	0.66
Eigen_PC	Uncertain	0.65
FATHMM_MKL	Pathogenic	0.98	D
LIST_S2	Uncertain	0.88	D;T
M_CAP	Pathogenic	1.0	D
MetaRNN	Pathogenic	0.95	D;D
MetaSVM	Pathogenic	1.1	D
MutationAssessor	Uncertain	2.0	M;M
PrimateAI	Pathogenic	0.88	D
PROVEAN	Uncertain	-3.1	D;D
REVEL	Pathogenic	0.81
Sift	Uncertain	0.0020	.;D
Sift4G	Uncertain	0.013	D;D
Polyphen		0.99	D;D
Vest4		0.70
MutPred		0.80		Loss of stability (P = 0.0222);Loss of stability (P = 0.0222);
MVP		1.0
MPC		1.0
ClinPred		0.99	D
GERP RS		5.4
Varity_R		0.96
gMVP		0.99

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs786202787; hg19: chr3-10183769; COSMIC: COSV56562607; COSMIC: COSV56562607;